[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613901":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":20,"responsibleParty":41,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":10,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Region Stockholm","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with Suspected or Known Brain Metastases",null,"Participants undergoing clinically indicated brain MRI with gadolinium contrast who will receive both conventional T1-weighted imaging and the novel gadolinium-weighted MRI sequence during the same scan session. The purpose is to compare lesion detection and conspicuity between the two sequences.",[13],"Diagnostic Test: Novel Gadolinium-Weighted MRI Sequence",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Novel Gadolinium-Weighted MRI Sequence","A post-contrast MRI sequence incorporating magnetization transfer (MT) preparation and flow-nulling with motion-sensitized driven equilibrium (MSDE). The sequence is optimized to suppress background tissue and vascular signal while enhancing the visibility of gadolinium-enhancing brain metastases. It is compared to conventional T1-weighted imaging in the same exam session.",[9],[21],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Karolinska University Hospital","RECRUITING","Stockholm","Solna","1171 76","Sweden","SE",{"type":30,"coordinates":31},"Point",[32,33],18.06871,59.32938,{"lat":33,"lon":32},[36],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"Johan Lundberg, Associate professor","CONTACT","+46725802949","johan.h.lundberg@regionstockholm.se",{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100613901","detection-of-brain-metastases-using-a-novel-gadolinium-weighted-mri-sequence-a-prospective-comparison-100613901",false,"NCT07272616","Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison","A Prospective Comparative Study of a Novel Gadolinium-Weighted MRI Sequence Versus Conventional T1-Weighted Imaging for the Detection of Brain Metastases","GDW","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled for clinical brain MRI with gadolinium contrast\n* Known or suspected brain metastases\n* Able to provide informed consent\n* Able to lie still for the duration of the MRI examination\n\nExclusion Criteria:\n\n* Contraindications to MRI\n* Known allergy or contraindication to gadolinium-based contrast agents\n* Renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n* Pregnant or breastfeeding\n* Inability to comply with study procedures","ALL","18 Years",{"count":54,"type":55},100,"ESTIMATED","OBSERVATIONAL","This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel \"gadolinium-weighted\" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.",[59],"Brain Neoplasms","2026-01-29",{"date":62,"type":63},"2026-01-30","ACTUAL",{"date":65,"type":63},"2026-01-28",{"date":67,"type":55},"2027-12-31",{"name":5,"class":6},1]